![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Woodward Pharma Services LLC, has acquired Lovaza (LO-VEY-ZA) soft gelatin capsules indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater than or equal to 500 mg/dL) hypertriglyceridemia from GlaxoSmithKline LLC (GSK).
Lead Product(s): Omega-3-Acid Ethyl Esters 90
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lovaza
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Woodward Pharma Services
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 18, 2021